44In that respect, it is important to recall that the provisions in Section 5 are not only specific but also exhaustive (judgment in Glaxosmithkline and Laboratoires Glaxosmithkline, C‑462/06, EU:C:2008:299, paragraph 18).
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.